{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T22:04:07Z","timestamp":1773007447260,"version":"3.50.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,9,1]],"date-time":"2014-09-01T00:00:00Z","timestamp":1409529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1016\/j.jns.2014.06.013","type":"journal-article","created":{"date-parts":[[2014,6,17]],"date-time":"2014-06-17T19:46:23Z","timestamp":1403034383000},"page":"193-197","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":25,"title":["Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy"],"prefix":"10.1016","volume":"344","author":[{"given":"M.A.","family":"Hellmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Lev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Lotan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mosberg-Galili","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Inbar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Luckman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fichman-Horn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Yakimov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Steiner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2014.06.013_bb0005","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMct1101691","article-title":"Fingolimod for multiple sclerosis","volume":"366","author":"Pelletier","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2014.06.013_bb0010","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1177\/1352458512458009","article-title":"Severe multiple sclerosis reactivation under fingolimod 3months after natalizumab withdrawal","volume":"18","author":"Daelman","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2014.06.013_bb0015","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/1352458511431973","article-title":"Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder","volume":"18","author":"Min","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2014.06.013_bb0020","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1177\/1352458512464282","article-title":"Switching therapy from natalizumab to fingolimod in relapsing\u2013remitting multiple sclerosis: clinical and magnetic resonance imaging findings","volume":"18","author":"Rinaldi","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2014.06.013_bb0025","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1177\/1352458513490549","article-title":"Frequent early multiple sclerosis relapses during treatment with fingolimod: a paradoxical effect?","volume":"19","author":"Ferraro","year":"2013","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2014.06.013_bb0030","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1212\/WNL.0b013e3182735c7a","article-title":"Severe relapses under fingolimod treatment prescribed after natalizumab","volume":"79","author":"Centonze","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.06.013_bb0035","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1212\/WNL.0b013e31824c46ad","article-title":"Severe multiple sclerosis relapse under fingolimod therapy: incident or coincidence?","volume":"78","author":"Castrop","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.06.013_bb0040","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00415-012-6744-7","article-title":"Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients","volume":"260","author":"Ghezzi","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2014.06.013_bb0045","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1001\/archneurol.2011.1057","article-title":"Rebound of disease activity after withdrawal of fingolimod (FTY720) treatment","volume":"69","author":"Havia","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.jns.2014.06.013_bb0050","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1007\/s00415-013-6933-z","article-title":"Rebound after Fingolimod suspension in a pediatric-onset multiple sclerosis patient","volume":"260","author":"Piscolla","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.jns.2014.06.013_bb0055","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1212\/WNL.0b013e3182735cb3","article-title":"Tumefactive multiple sclerosis lesions under fingolimod treatment","volume":"79","author":"Visser","year":"2012","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.06.013_bb0060","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1056\/NEJMoa0907839","article-title":"Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis","volume":"362","author":"Cohen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jns.2014.06.013_bb0065","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1212\/01.wnl.0000344567.51394.e3","article-title":"Hemorrhaging focal encephalitis under fingolimod (FTY720) treatment: a case report","volume":"72","author":"Leypoldt","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.06.013_bb0070","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1177\/1352458512463768","article-title":"Emerging tumefactive multiple sclerosis after switching therapy from natalizumab to fingolimod","volume":"18","author":"Jander","year":"2012","journal-title":"Mult Scler"},{"key":"10.1016\/j.jns.2014.06.013_bb0075","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1212\/WNL.0b013e31829deeb4","article-title":"Tumefactive multiple sclerosis lesions under fingolimod treatment","volume":"81","author":"Kinney","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.06.013_bb0080","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1212\/01.wnl.0000435293.34351.11","volume":"81","author":"Pilz","year":"2013","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.06.013_bb0090","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1093\/brain\/awn098","article-title":"Clinical and radiographic spectrum of pathologically confirmed tumefactive multiple sclerosis","volume":"131","author":"Lucchinetti","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.jns.2014.06.013_bb0095","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/bjo.59.6.334","article-title":"Homonymous hemianopia in multiple sclerosis with report of bilateral case","volume":"59","author":"Hawkins","year":"1975","journal-title":"Br J Ophthalmol"},{"key":"10.1016\/j.jns.2014.06.013_bb0100","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nrmicro2712","article-title":"Immune reconstitution inflammatory syndrome: the trouble with immunity when you had none","volume":"10","author":"Barber","year":"2012","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.jns.2014.06.013_bb0105","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/S1474-4422(10)70122-8","article-title":"PML: underdiagnosed in MS patients on natalizumab","volume":"9","author":"Steiner","year":"2010","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jns.2014.06.013_bb0110","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1212\/WNL.0b013e31820d9507","article-title":"The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators","volume":"76","author":"Soliven","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2014.06.013_bb0115","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1212\/01.wnl.0000435305.95271.84","article-title":"Tumefactive multiple sclerosis and fingolimod. Immunotherapies and unintended consequences","volume":"81","author":"Friedemann","year":"2013","journal-title":"Neurology"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14003839?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X14003839?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T15:43:13Z","timestamp":1758382993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X14003839"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":22,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["S0022510X14003839"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2014.06.013","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2014.06.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}